Daxor (DXR) Validates Blood Volume Analysis Accuracy in New Clinical Study

Key Facts

1Daxor's Blood Volume Analysis (BVA) technology was validated as uniquely accurate compared to standard capillary leak indices.

2The clinical data was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress.

3The study focused on the mechanistic specificity of capillary leak indices, validated in heart failure cases.

Daxor Corporation (Nasdaq: DXR) announced positive clinical data validating its proprietary Blood Volume Analysis (BVA) technology. The findings, presented at the Society for Critical Care Medicine (SCCM) 2026 Congress, highlight the technology's superior accuracy compared to traditional capillary leak indices. The study specifically focused on the mechanistic specificity of these indices, with validation conducted in heart failure cases. This clinical validation marks a significant milestone for Daxor, reinforcing the diagnostic value of its BVA technology in critical care settings. By providing more precise measurements, the technology aims to improve patient outcomes in complex medical scenarios. Investors view this development as a positive step toward broader clinical adoption and market penetration for the medical technology firm.